Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBT for 16 consecutive years, with $7.6 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 80.23% to $7.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.2 million, a 128.46% increase, with the full-year FY2024 number at $16.2 million, up 121.0% from a year prior.
  • EBT was $7.6 million for Q3 2025 at Gyre Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $51.6 million in Q2 2022 to a low of -$73.2 million in Q4 2023.
  • A 5-year average of -$6.3 million and a median of -$1.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 453.2% in 2021, then skyrocketed 4455.11% in 2024.
  • Gyre Therapeutics' EBT stood at -$20.4 million in 2021, then dropped by 11.84% to -$22.8 million in 2022, then tumbled by 221.02% to -$73.2 million in 2023, then soared by 100.91% to $665000.0 in 2024, then soared by 1047.22% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBT are $7.6 million (Q3 2025), $2.2 million (Q2 2025), and $4.6 million (Q1 2025).